A Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2010年 / 52卷 / 1340期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [21] Immune Tolerance Induction in Severe Hemophilia a Patients Using Wilate, a Von Willebrand Factor/Factor VIII Concentrate
    Wu, John K.
    Woo, Celina
    Crilly, Erica
    BLOOD, 2014, 124 (21)
  • [22] Pharmacokinetic evaluation before surgery of two patients affected by von Willebrand disease and treated with von Willebrand factor/factor VIII concentrate Wilate®
    Preti, P. S.
    Bertolino, G.
    Spataro, C.
    Ciola, M.
    Ambaglio, C.
    HAEMOPHILIA, 2019, 25 : 153 - 153
  • [23] Characterisation of the novel, high purity, double virus inactivated von Willebrand factor and factor VIII concentrate Wilate®
    Stadler, M
    Gruber, G
    Kannicht, C
    Biesert, L
    Radomski, KU
    Suhartono, H
    Pock, K
    Neisser-Svae, A
    Weinberger, J
    Roemisch, J
    Svae, TE
    BLOOD, 2005, 106 (11) : 97B - 97B
  • [24] Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate
    Berntorp, E.
    Windyga, J.
    HAEMOPHILIA, 2009, 15 (01) : 122 - 130
  • [25] ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates
    Peyvandi, Flora
    Mannucci, Pier Mannuccio
    Valsecchi, Carla
    Pontiggia, Silvia
    Bernstein, Jonathan
    Guazzini, Stefano
    Retzios, Anastassios
    BLOOD, 2012, 120 (21)
  • [26] Plasma-derived, purified, pasteurised von Willebrand factor/factor VIII concentrate in the treatment of patients with von Willebrand disease and haemophilia a: update of a long-term observational study
    Wermes, C.
    Holzhauer, S.
    Halimeh, S.
    Kemkes-Matthes, B.
    Sommerer, P.
    Wieland, I
    Krause, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 497 - 497
  • [27] Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups
    Sidonio Jr, Robert F.
    BLOOD, 2024, 144 : 3985 - 3985
  • [28] Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate®)
    Stadler, M.
    Gruber, G.
    Kannicht, C.
    Biesert, L.
    Radomski, K. U.
    Suhartono, H.
    Pock, K.
    Neisser-Svae, A.
    Weinberger, J.
    Roemisch, J.
    Svae, T. -E.
    BIOLOGICALS, 2006, 34 (04) : 281 - 288
  • [29] Effect of recombinant and plasma-derived von Willebrand Factor on the procoagulant activity of factor VIII in thrombin generation assays
    Knappe, Sabine
    Till, Susanne
    Scheiflinger, Friedrich
    Dockal, Michael
    HAEMOPHILIA, 2014, 20 : 28 - 28
  • [30] Use of a plasma-derived high-purity and double viral inactivated factor VIII concentrate in the treatment of von Willebrand disease
    Villar, A
    Jimenez-Yuste, V
    Canales, M
    Morado, M
    Gago, J
    Sanjurjo, MJ
    Quintana, M
    Magallon, M
    Hernandez-Navarrro, F
    THROMBOSIS AND HAEMOSTASIS, 1999, : 796 - 796
12345